EMPACON L 25/5 TABLET

Product Description

EMPACON L 25/5 TABLET
Empagliflozin 25 mg + Linagliptin 5 mg

Product Description:

EMPACON L 25/5 TABLET is an advanced oral antidiabetic combination formulated with Empagliflozin 25 mg and Linagliptin 5 mg, designed to deliver comprehensive glycemic control in adults with Type 2 Diabetes Mellitus. This dual-action DPP-4 inhibitor and SGLT2 inhibitor therapy enhances insulin function and promotes glucose excretion, supporting better metabolic outcomes.

Key Benefits:

• Dual mechanism improves fasting and postprandial blood glucose levels

• Reduces HbA1c with minimal risk of hypoglycemia

• Supports cardiovascular and renal protection in diabetic patients

• Convenient once-daily dosing improves adherence

Usage/Application:
Indicated as an adjunct to diet and exercise for managing Type 2 diabetes, particularly in patients requiring a combination of SGLT2 and DPP-4 inhibitors. Widely used in diabetology, general medicine, and endocrinology practices.

Composition:

• Empagliflozin 25 mg

• Linagliptin 5 mg

• Excipients q.s.

Target Buyers:
Ideal for pharma distributors, diabetic care retailers, hospital supply chains, and bulk buyers seeking high-efficacy antidiabetic formulations with consistent quality and regulatory compliance.

Availability:

Ready for bulk procurement, private labeling, and pharma distribution partnerships across India and export markets.